Clinical Trials Browser

Completed × Interventional × Urinary Bladder Diseases × Clear all

Urinary Bladder Diseases, Carcinogenesis

NCT03081858 2025-06-27

Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Diseases, Urinary Bladder Neoplasms, Urogenital Neoplasms, Urologic Diseases, Urologic Neoplasms

NCT04200963 2024-03-15

A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma

Phase 1 Completed

78 enrolled

Genitourinary

Urinary Bladder Diseases, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasm Metastasis, Neoplasms

NCT03257293 2021-04-27

A Trial of a Modified Cystoscopy Method to Reduce Pain Perception

Phase NA Completed

93 enrolled

Genitourinary

Urinary Bladder Diseases, Urinary Bladder Neoplasms, Hematuria

NCT03591367 2019-11-04

The Potential Role Of MicroRNA-155 And Telomerase Reverse Transcriptase In Diagnosis Of Non-Muscle Invasive Bladder Cancer And Their Pathological Correlation

Phase NA Completed

115 enrolled

Genitourinary

Urinary Bladder Diseases, Urinary Bladder Neoplasms

NCT02300610 2019-08-01

Enzalutamide in Combination With Gemcitabine and Cisplatin in Bladder Cancer

Phase 1 Completed

10 enrolled 14 charts

Genitourinary

Urinary Bladder Diseases, Urinary Bladder Neoplasms, Carcinoma, Carcinoma, Transitional Cell, Ureteral Diseases, Ureteral Neoplasms, Urethral Neoplasms

NCT01803295 2017-06-16

OPTIMA

Phase NA Completed

80 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Diseases, Urinary Bladder Neoplasms, Urologic Diseases, Urologic Neoplasms

NCT02307487 2017-06-16

Safety of Pre-TURBT Intravesical Instillation of Escalating Doses of TC-3 Gel and MMC in NMIBC Patients

Phase 2 Completed

14 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Diseases, Urinary Bladder Neoplasms, Neoplasms, Urologic Diseases, Urologic Neoplasms

NCT02891460 2016-09-08

Pilot Study to Evaluate the Clinical Response to Mitomycin-C in Hydrogel (TC-3) Administered Intravesically in NMIBC Patients

Phase NA Completed

18 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Diseases, Urinary Bladder Neoplasms, Neoplasms, Urologic Diseases, Urologic Neoplasms

NCT00753415 2015-03-17

A Study of V934/V935 Vaccine in Cancer Participants With Selected Solid Tumors (V934-002)

Phase 1 Completed

37 enrolled 10 charts

BreastDermatologicEndocrineGastrointestinalGenitourinaryNETThoracic

Adenocarcinoma, Urinary Bladder Diseases, Urinary Bladder Neoplasms, Breast Diseases, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colonic Neoplasms, Genital Diseases, Male, Intestinal Neoplasms, Kidney Diseases, Kidney Neoplasms, Melanoma, Neoplasms, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Prostatic Diseases, Prostatic Neoplasms, Skin Diseases, Urogenital Neoplasms, Urologic Diseases, Urologic Neoplasms, Colorectal Neoplasms, Neuroectodermal Tumors, Nevi and Melanomas, Neuroendocrine Tumors

Clinical Trials

The COOKER-BLADDER Trial

Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer

A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma

A Trial of a Modified Cystoscopy Method to Reduce Pain Perception

The Potential Role Of MicroRNA-155 And Telomerase Reverse Transcriptase In Diagnosis Of Non-Muscle Invasive Bladder Cancer And Their Pathological Correlation

Enzalutamide in Combination With Gemcitabine and Cisplatin in Bladder Cancer

OPTIMA

Safety of Pre-TURBT Intravesical Instillation of Escalating Doses of TC-3 Gel and MMC in NMIBC Patients

Pilot Study to Evaluate the Clinical Response to Mitomycin-C in Hydrogel (TC-3) Administered Intravesically in NMIBC Patients

A Study of V934/V935 Vaccine in Cancer Participants With Selected Solid Tumors (V934-002)